Last reviewed · How we verify
DTap-HepB-IPV-Hib vaccine
DTap-HepB-IPV-Hib vaccine is a Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 2 development. Also known as: Hexyon®, Vaxelis®, Infanrix hexa®.
At a glance
| Generic name | DTap-HepB-IPV-Hib vaccine |
|---|---|
| Also known as | Hexyon®, Vaxelis®, Infanrix hexa® |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
- Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants (PHASE1, PHASE2)
- Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age (PHASE2)
- A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy Adults (PHASE1)
- Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008) (PHASE3)
- Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination (PHASE3)
- Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™ (PHASE3)
- Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DTap-HepB-IPV-Hib vaccine CI brief — competitive landscape report
- DTap-HepB-IPV-Hib vaccine updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI
Frequently asked questions about DTap-HepB-IPV-Hib vaccine
What is DTap-HepB-IPV-Hib vaccine?
DTap-HepB-IPV-Hib vaccine is a Biologic drug developed by Sanofi Pasteur, a Sanofi Company.
Who makes DTap-HepB-IPV-Hib vaccine?
DTap-HepB-IPV-Hib vaccine is developed by Sanofi Pasteur, a Sanofi Company (see full Sanofi Pasteur, a Sanofi Company pipeline at /company/sanofi).
Is DTap-HepB-IPV-Hib vaccine also known as anything else?
DTap-HepB-IPV-Hib vaccine is also known as Hexyon®, Vaxelis®, Infanrix hexa®.
What development phase is DTap-HepB-IPV-Hib vaccine in?
DTap-HepB-IPV-Hib vaccine is in Phase 2.
Related
- Manufacturer: Sanofi Pasteur, a Sanofi Company — full pipeline
- Also known as: Hexyon®, Vaxelis®, Infanrix hexa®
- Compare: DTap-HepB-IPV-Hib vaccine vs similar drugs
- Pricing: DTap-HepB-IPV-Hib vaccine cost, discount & access